SGSheng Gao

Sheng Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sheng Gao has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Chunyan Hua

    School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China

    9 shared publications
  • Shenghao Huang

    School of the 2nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China

    4 shared publications
  • Deqi Wang

    The First School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China

    3 shared publications
  • Lingjie Kong

    School of the 2nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China

    3 shared publications
  • Qianru Yang

    The First School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China

    3 shared publications
  • Siyan Chen

    School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, China

    3 shared publications

Latest Publications

  • ACSL1 orchestrates ferroptosis and degranulation in low-density neutrophils: a novel pathogenic mechanism and therapeutic target in systemic lupus erythematosus

    by Wenqian Wang, Tiancheng Qi, Jinlin Yang, Yirui Fu, Huan Zhang, Xinyue Liang, Zhongkai Zhang, Guoguo Fu, Sheng Gao, Chunyan Hua

  • Identification of childhood-onset lupus nephritis through integrative bioinformatics: otoferlin as a novel biomarker

    by Xinlei Wu, Xinyue Liang, Yang Li, Siyan Chen, Yuanyuan Xie, Chunyan Hua, Sheng Gao

    Childhood-onset systemic lupus erythematosus (cSLE) exhibits a higher incidence of lupus nephritis (LN) compared to adult-onset SLE (aSLE). However, the underlying molecular mechanisms remain elusive. Gene expression datasets from childhood-onset (GSE65391) and adult-onset (GSE72798) LN patients were obtained. Differential gene expression (DEG) and weighted gene co-expression network analysis (WGCNA) identified key modules associated with cLN. Machine learning algorithms (random forest, SVM-RFE) prioritized hub genes, validated by ROC curves. Immune cell profiles analysis (CIBERSORT, ssGSEA, xCell) evaluated immune cell profiles, and functional enrichment (GSEA, GSVA) explored pathway alterations. Molecular docking and drug sensitivity analysis predicted therapeutic targets for otoferlin (OTOF)-high cLN. Distinct gene expression profiles were revealed between cLN and aLN, with significant enrichment of interferon (IFN) pathways in cLN. OTOF emerged as a high diagnostic biomarker for cLN, and was positively correlated with activated dendritic cells and associated with the TLR signaling pathway in cLN. Molecular docking predicted strong binding of OTOF to JAK inhibitors, supported by CMap analysis showing sensitivity of OTOF-high cLN to these drugs. IFN-related pathways are crucial for the pathogenesis of cLN. OTOF is a promising blood biomarker and contributes to cLN progression through IFN-related pathways. The molecular mechanisms by which cSLE is more likely to progress to cLN than aSLE are rarely investigated. The crucial role of interferon pathways in cLN pathogenesis is highlighted. OTOF could serve as an early diagnostic biomarker for cLN and promote cLN progression through TLRs. These insights could guide tailored therapeutic strategies for cLN, addressing a critical gap in current clinical management.


  • Palmitoylation Dynamics in Systemic Lupus Erythematosus: Multi‐Omics Insights and Potential Therapeutic Implications

    by Zeyu Liu, Yanggang Hong, Guo Hua, Zixi Li, Chunyan Hua, Sheng Gao

    Objective: Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by immune dysregulation. The role of palmitoylation in regulating immune responses and its contribution to SLE pathogenesis remains insufficiently understood. Methods: We conducted a multi‐omics analysis using the GSE61635 dataset to identify differentially expressed genes (DEGs) in SLE. Palmitoylation‐related genes (PRGs) were identified through differential expression analysis, weighted gene co‐expression network analysis (WGCNA), and machine learning models. Single‐cell RNA sequencing (scRNA‐seq) was used to assess immune cell dynamics, and Mendelian randomization (MR) was employed to explore causal relationships between metabolites and SLE. Results: We identified 3946 DEGs and 13 key PRGs associated with palmitoylation in SLE. Four hub genes (ACSL1, ZDHHC12, GPX1, and DDHD2) were highlighted as potential biomarkers. Functional enrichment analysis revealed that these genes are involved in fatty acid metabolism and immune signaling. scRNA‐seq analysis showed increased palmitoylation activity in neutrophils and cytotoxic T lymphocytes (CTLs) in SLE. MR analysis identified four phospholipids containing palmitic acid as causally linked to SLE. Conclusion: This study identifies ACSL1 and ZDHHC12 as potential therapeutic targets for modulating palmitoylation and immune responses in SLE. Further research is required to validate these findings and explore their clinical implications for SLE treatment.


  • Open Access

    Prioritizing endocrine-disrupting chemicals targeting systemic lupus erythematosus genes via Mendelian randomization and colocalization analyses

    by Yanggang Hong, Wanyi Shu, Xiaoyang Jiang, Yi Wang, Rujie Chen, Qianru Yang, Deqi Wang, Chenyou Shao, Sheng Gao, Chunyan Hua


  • Exploring the molecular mechanism of Tripterygium Wilfordii Hook F in treating systemic lupus erythematosus via network pharmacology and molecular docking

    by Yanggang Hong, Deqi Wang, Hengrong Qian, Xiaoyang Jiang, Yi Wang, Xinyue Liang, Sheng Gao, Chunyan Hua

    Background Tripterygium wilfordii Hook F (TwHF) is a prominent Chinese herbal formula. It exhibits significant clinical efficacy in treating systemic lupus erythematosus (SLE), though its mechanisms remain unclear. Our study employs network pharmacology and molecular docking to explore active compounds of TwHF and their associated targets for SLE treatment. Methods Primary active compounds of TwHF and their targets were sourced from the TCMSP, SwissTargetPrediction, and UniProt databases. SLE-relevant target proteins were identified from the OMIM and GeneCards databases. Enrichment analyses were conducted to reveal results of common TwHF-SLE targets. STRING and Cytoscape software were used to systematically analyze and construct protein–protein interaction (PPI) networks, compound-target-pathway, and target-organ networks. Molecular docking was utilized to confirm the binding of key targets to the top active compounds. Results A total of 14 active compounds and 300 overlapping targets between TwHF and SLE were identified. PPI network analysis revealed 29 core targets. Several pathways were found to contribute to the potential therapeutic effects of TwHF in SLE, including PI3K-Akt signaling pathway, Th17 cell differentiation, chemokine signaling, and T cell receptor signaling. Disease Ontology (DO) analysis highlighted the involvement of TwHF in genes associated with myocardial infarction (MI), atherosclerosis (AS), breast carcinoma, and ischemia. Molecular docking results demonstrated strong binding affinities, with 37 signal molecule-receptor interactions in SLE and 97 interactions in SLE-related MI and AS showing binding energies lower than -7 kJ/mol. Conclusions This research effectively anticipates the potent constituents, probable targets, and pathways implicated in treating SLE with TwHF, specifically addressing complications such as MI and AS. Comprehending the precise molecular mechanism targeting SLE of TwHF and its efficacious bioactive components furnishes a theoretical groundwork for enhancing its clinical utilization. Key Points •SLE is characterized by aberrant immune activation and persistent inflammation. •TwHF exerts immunomodulatory and anti-inflammatory effects. •TwHF exhibits prospects in the treatment of SLE with unknown molecular mechanisms. •Network pharmacology and molecular docking reveal promise in the mechanism of TwHF.


  • Top Cited Papers
    Open Access

    Environmental triggers and future risk of developing autoimmune diseases: Molecular mechanism and network toxicology analysis of bisphenol A

    by Yanggang Hong, Deqi Wang, Yinfang Lin, Qianru Yang, Yi Wang, Yuanyuan Xie, Wanyi Shu, Sheng Gao, Chunyan Hua


  • Open Access

    Crucial Roles of RSAD2/viperin in Immunomodulation, Mitochondrial Metabolism and Autoimmune Diseases

    by Siyan Chen, Jiani Ye, Yinfang Lin, Wenxiu Chen, Shenghao Huang, Qianru Yang, Hengrong Qian, Sheng Gao, Chunyan Hua

    Autoimmune diseases are typically characterized by aberrant activation of immune system that leads to excessive inflammatory reactions and tissue damage. Nevertheless, precise targeted and efficient therapies are limited. Thus, studies into novel therapeutic targets for the management of autoimmune diseases are urgently needed. Radical S-adenosyl methionine domain-containing 2 (RSAD2) is an interferon-stimulated gene (ISG) renowned for the antiviral properties of the protein it encodes, named viperin. An increasing number of studies have underscored the new roles of RSAD2/viperin in immunomodulation and mitochondrial metabolism. Previous studies have shown that there is a complex interplay between RSAD2/vipeirn and mitochondria and that binding of the iron-sulfur (Fe-S) cluster is necessary for the involvement of viperin in mitochondrial metabolism. Viperin influences the proliferation and development of immune cells as well as inflammation via different signaling pathways. However, the function of RSAD2/viperin varies in different studies and a comprehensive overview of this emerging theme is lacking. This review will describe the characteristics of RSAD2/viperin, decipher its function in immunometabolic processes, and clarify the crosstalk between RSAD2/viperin and mitochondria. Furthermore, we emphasize the crucial roles of RSAD2 in autoimmune diseases and its potential application value.


  • Challenges and opportunities in inflammatory bowel disease: from current therapeutic strategies to organoid-based models

    by Lingjie Kong, Siyan Chen, Shenghao Huang, Anzhe Zheng, Sheng Gao, Jianzhong Ye, Chunyan Hua

    Background Inflammatory bowel disease (IBD) is an increasingly prevalent global health concern that has garnered substantial attention. However, the underlying mechanisms are still unclear and the current treatments have significant limitations. Intestinal organoids provide an in vitro model to explore the pathogenesis, test the therapeutic effects, and develop regenerative treatments as well as offer the potential to transform drug discovery of IBD. Methods To advance our understanding of the whole story of IBD spanning from the pathogenesis to the current therapeutic strategies and latest advancements, a comprehensive search of major databases including PubMed, Scopus, and Web of Science was conducted to retrieve original articles and reviews related to IBD, organoids, pathogenesis and therapy. Results This review deciphers the etiopathogenesis and the current therapeutic approaches in the treatment of IBD. Notably, critical aspects of intestinal organoids in IBD, such as their potential applications, viability, cell renewal ability, and barrier functionality are highlighted. We also discuss the advances, limitations, and prospects of intestinal organoids for precision medicine. Conclusion The latest strides made in research about intestinal organoids help elucidate intricate aspects of IBD pathogenesis, and pave the prospective avenues for novel therapeutic interventions.


  • Insights into the complex interactions between Rab22a and extracellular vesicles in cancers

    by Shenghao Huang, Yuxuan Bao, Lingjie Kong, Sheng Gao, Chunyan Hua

    Introduction Oncogenic Ras-related GTP-binding proteins, referred to as Rabs, are characterized by their intricate interactions with upstream, downstream molecules, and notably, extracellular vesicles (EVs). While the expansive family of Rabs and their associated signaling pathways have been exhaustively dissected, Rab22a emerges as an entity of outstanding interest, owing to its potent influence in many biological processes and its conspicuous correlation with cancer metastasis and migration. A burgeoning interest in the interactions between Rab22a and EVs in the field of oncology underscores the necessity for more in-depth reviews and scholarly discourses. Methods We performed a review based on published original and review articles related to Rab22a, tumor, microRNA, exosome, microvesicles, EVs, CD147, lysosome, degradation, endosomal recycling, etc. from PubMed, Web of Science and Google Scholar databases. Results and conclusions We summarize the regulatory processes governing the expression of Rab22a and the mutants of Rab22a. Notably, the present understanding of complex interactions between Rab22a and EVs are highlighted, encompassing both the impact of Rab22a on the genesis of EVs and the role of EVs that are affected by Rab22a mutants in propelling tumor advancement. The dynamic interaction between Rab22a and EVs plays a significant role in the progression of tumors, and it can provide novel insights into the pathogenesis of cancers and the development of new therapeutic targets.


  • Crucial roles of Rab22a in endosomal cargo recycling

    by Lingjie Kong, Shenghao Huang, Yuxuan Bao, Yingtong Chen, Chunyan Hua, Sheng Gao

    Endosomal cargo recycling lies at the heart of subcellular trafficking processes under the management of several Ras‐related GTP‐binding proteins (Rabs) which are coordinated by their upstream regulators and require their downstream effectors to display their functions. In this regard, several Rabs have been well‐reviewed except Rab22a. Rab22a is a crucial regulator of vesicle trafficking, early endosome and recycling endosome formation. Notably, recent studies demonstrated the immunological roles of Rab22a, which are closely associated with cancers, infection and autoimmune disorders. This review provides an overview of the regulators and effectors of Rab22a. Also, we highlight the current knowledge of the role of Rab22a in endosomal cargo recycling, including the biogenesis of recycling tubules with the help of a complex with Rab22a at its core, and how different internalized cargo chooses different recycling routes thanks to the cooperation of Rab22a, its effectors and its regulators. Of note, contradictions and speculation related to endosomal cargo recycling that Rab22a brings impacts on are also discussed. Finally, this review endeavors to briefly introduce the various events impacted by Rab22a, particularly focusing on the commandeered Rab22a‐associated endosomal maturation and endosomal cargo recycling, in addition to the extensively investigated oncogenic role of Rab22a.